CCRP Exam Flashcards

Q: What is the SOCRA CCRP exam pass rate?

SOCRA does not publish an official pass-rate statistic on its examination-results page -- score reports simply state pass/fail plus a content-area breakdown for unsuccessful candidates. Third-party aggregations citing SOCRA data report roughly 72% for 2024 (2,044 candidates), with a 2020-2025 range of about 64-75%, but treat those figures as unofficial estimates rather than a SOCRA-published statistic.

Q: How many questions are on the CCRP exam, and how is the passing score set?

The exam has 130 multiple-choice questions: 100 scored and 30 unscored pilot items mixed in unidentified, so every question must be answered as if it counts. You must answer 71 of the 100 scored questions correctly (71%) to pass. SOCRA sets that cut score using the Modified Angoff method, a panel-based standard-setting process, and there is no penalty for guessing.

Q: What happens if I fail the CCRP exam -- how soon can I retest?

SOCRA requires a 15-day waiting period before you may retest, plus a $275 retest fee and a $115 (North America) or $175 (international) testing-center fee. You can retake the exam under this standard policy for up to 3 unsuccessful attempts; before a 4th attempt, SOCRA requires proof of 6 hours of GCP education/training in addition to the standard wait.

Q: How is the SOCRA CCRP different from ACRP's CCRC/CCRA or AACVPR's CCRP?

SOCRA's CCRP is one comprehensive credential covering all clinical-research roles and tests both U.S. federal regulations and ICH GCP; ACRP instead offers role-specific credentials (CCRC for coordinators, CCRA for monitors) testing ICH GCP only. AACVPR also uses the initials 'CCRP,' but for an unrelated Certified Cardiac Rehabilitation Professional credential in cardiac/pulmonary rehab -- it has nothing to do with clinical trials and is a completely different exam.

Q: What changed on the CCRP exam for 2026?

Starting January 1, 2026, SOCRA's exam content reflects ICH E6(R3), the revised Good Clinical Practice guideline adopted in January 2025. Key additions are an emphasis on quality by design, proportionality (risk-based oversight scaled to actual risk), identifying critical data/processes up front, and fit-for-purpose use of trial technology.

Q: What are the three CCRP exam domains and their weights?

Research Study Start-Up is 40% of the exam (ethics, IRB/IEC requirements, informed consent, IND/IDE applications), Research Study Implementation is 50% (adverse-event reporting, monitoring, protocol compliance, IP accountability), and Research Study Closure is 10% (close-out visits, record retention, final regulatory notifications).

Question 1

Nuremberg Code (1947)

Accepted Answer

Established after the Nazi doctors' trial; its first principle makes voluntary, informed consent an absolute prerequisite for research participation. It has no legal force but is the ethical foundation for later codes and regulations.

Question 2

Declaration of Helsinki (World Medical Association, 1964)

Accepted Answer

The first international ethics guideline written specifically for physician-researchers conducting human experimentation. Introduced the idea of independent ethics-committee review of research and is periodically revised by the WMA.

Question 3

Belmont Report (1979) -- the three core principles

Accepted Answer

Respect for Persons (autonomy/informed consent, extra protection for those with diminished autonomy), Beneficence (maximize benefit, minimize harm), and Justice (fair distribution of research burdens and benefits across populations).

Question 4

The Common Rule (45 CFR 46, Subpart A)

Accepted Answer

The U.S. federal regulation that turns Belmont's principles into enforceable requirements for federally funded human-subjects research: mandatory IRB review and informed consent, plus (Subparts B/C/D) added protections for pregnant women/fetuses/neonates, prisoners, and children.

Question 5

Nuremberg vs. Helsinki vs. Belmont vs. the Common Rule -- what's the difference?

Accepted Answer

Nuremberg (1947): first ethics code, consent as an absolute rule, no legal force. Helsinki (1964, WMA): physician-research ethics guideline, introduced ethics-committee review. Belmont (1979): U.S. ethical framework (3 principles), not itself a regulation. Common Rule (45 CFR 46): the U.S. federal regulation with actual legal force that operationalizes Belmont.

Question 6

Minimum IRB membership requirements (21 CFR 56.107 / 45 CFR 46.107)

Accepted Answer

At least 5 members with varying backgrounds, including at least 1 member whose primary concerns are scientific, at least 1 whose primary concerns are nonscientific, and at least 1 member unaffiliated with the institution (and not an immediate family member of anyone affiliated).

Question 7

Expedited IRB review -- when is it used, and what can't it do?

Accepted Answer

Used for minimal-risk research or minor changes to already-approved studies that fit specific listed categories (e.g., limited blood draws, certain noninvasive procedures). Conducted by the chair or a designated experienced reviewer, who may approve or request changes -- but only the convened full board can disapprove research.

Question 8

Full-board (convened) IRB review

Accepted Answer

Required for research that is more than minimal risk. Needs a quorum -- a majority of members present, including at least one nonscientific member -- and approval requires a majority vote of those present at the meeting.

Question 9

Can a subject be enrolled before IRB approval and informed consent are complete?

Accepted Answer

No -- with one narrow exception: the FDA emergency-research exception (21 CFR 50.24), which allows enrollment without prior consent only for specific life-threatening emergency circumstances meeting strict regulatory criteria and community consultation requirements.

Question 10

The 8 basic elements of informed consent (21 CFR 50.25(a))

Accepted Answer

(1) purpose/procedures/duration, (2) reasonably foreseeable risks, (3) reasonably expected benefits, (4) alternative procedures/treatments, (5) confidentiality of records, (6) compensation/treatment available if injury occurs (more-than-minimal-risk studies), (7) whom to contact about the research or a research-related injury, and (8) that participation is voluntary with the right to withdraw at any time without penalty.

Question 11

Additional (optional) consent elements (21 CFR 50.25(b))

Accepted Answer

Added 'when appropriate,' e.g.: unforeseeable risks (including to an embryo/fetus), circumstances under which the investigator may terminate participation without consent, added costs to the subject, consequences of withdrawing, a promise that significant new findings will be shared, and the approximate number of subjects in the study.

Question 12

When can an IRB waive or alter informed consent?

Accepted Answer

Only for research that is no more than minimal risk, where the waiver won't adversely affect subjects' rights/welfare, the research couldn't practicably be done without it, and subjects will be debriefed when appropriate -- a narrower, separate pathway from the 21 CFR 50.24 emergency-research exception.

Question 13

Assent vs. consent in pediatric research

Accepted Answer

Assent is an affirmative agreement obtained from the minor (age threshold set by the IRB, based on the child's developmental capacity), obtained IN ADDITION TO the parent's/guardian's permission -- it is a separate process, not a watered-down version of adult consent.

Question 14

21 CFR Part 11

Accepted Answer

Electronic Records; Electronic Signatures. Sets requirements for when e-records/e-signatures are considered trustworthy and legally equivalent to paper -- audit trails, system validation, and access controls.

Question 15

21 CFR Part 50

Accepted Answer

Protection of Human Subjects -- governs informed consent requirements (the 8 basic plus optional additional elements). Distinct from Part 56, which governs the IRB itself rather than the consent document.

Question 16

21 CFR Part 54

Accepted Answer

Financial Disclosure by Clinical Investigators -- requires sponsors to collect information about investigators' financial interests/arrangements (equity, compensation tied to outcome, etc.) so FDA can assess potential bias in study results.

Question 17

21 CFR Part 56

Accepted Answer

Institutional Review Boards -- establishes IRB composition, function, operating procedures, and recordkeeping requirements (this is where the >=5-member/1-scientific/1-nonscientific/1-unaffiliated rule lives).

Question 18

21 CFR Part 312 and the IND 30-day review clock

Accepted Answer

Governs Investigational New Drug applications for drug/biologic trials. Once a sponsor submits an IND, FDA has 30 calendar days to review it for safety before the sponsor may begin the clinical study -- unless FDA notifies the sponsor of a clinical hold.

Question 19

21 CFR Part 812 -- Significant Risk (SR) vs. Non-Significant Risk (NSR) devices

Accepted Answer

Governs Investigational Device Exemptions. SR device studies require a full IDE application to FDA plus IRB approval; NSR device studies are considered to have an 'approved' IDE once the sponsor obtains IRB approval and follows abbreviated requirements -- no separate FDA IDE submission needed.

Question 20

FDA Form 1571 vs. Form 1572

Accepted Answer

Form 1571 is the IND Application cover sheet, filed by the SPONSOR to open/maintain an IND. Form 1572 is the Statement of Investigator, signed by each participating INVESTIGATOR, attesting to qualifications and committing to conduct the study per protocol, ensure IRB oversight, obtain consent, and report adverse events.

Question 21

AE vs. SAE vs. SUSAR -- what's the difference?

Accepted Answer

AE (Adverse Event): any untoward medical occurrence in a subject, regardless of causality. SAE (Serious AE): an AE resulting in death, is life-threatening, requires/prolongs hospitalization, causes disability, or is a congenital anomaly. SUSAR: a Suspected Unexpected Serious Adverse Reaction -- serious, not described in the current safety information, and reasonably possibly related to the study drug.

Question 22

Investigator-to-sponsor SAE reporting timeline

Accepted Answer

Investigators must report serious adverse events to the sponsor immediately, and no later than 24 hours after becoming aware of the event, per ICH GCP.

Question 23

Sponsor-to-FDA reporting: fatal or life-threatening SUSARs

Accepted Answer

Must be reported to FDA (and all participating investigators) as soon as possible but no later than 7 calendar days after the sponsor's initial notification, as a preliminary report, followed by a complete follow-up report within 15 calendar days.

Question 24

Sponsor-to-FDA reporting: other serious, unexpected suspected adverse reactions

Accepted Answer

Must be reported to FDA in a written IND safety report no later than 15 calendar days after the sponsor determines the information qualifies for reporting.

Question 25

Reporting unanticipated problems to the IRB

Accepted Answer

Investigators must promptly report unanticipated problems involving risks to subjects or others to the IRB, per the institution's written policy -- this IRB-reporting timeline is separate from (and not necessarily identical to) the FDA's 7-/15-day IND safety-report clock.

Question 26

Adverse device effect reporting under an IDE

Accepted Answer

Sponsors of device studies must report unanticipated adverse device effects (UADEs) to FDA, the reviewing IRB(s), and all participating investigators within 10 working days of first learning of the effect.

Question 27

Data Safety Monitoring Board (DSMB)

Accepted Answer

An independent group (used especially in large, high-risk, or vulnerable-population trials) that periodically reviews accumulating safety and efficacy data and can recommend continuing, modifying, or stopping a trial early for safety or futility.

Question 28

The four classic monitoring visit types

Accepted Answer

Pre-study (site selection/qualification), Initiation (Site Initiation Visit -- staff training, activation), Routine/Interim (ongoing source data verification and compliance checks), and Close-out (final visit reconciling data and IP before study closure).

Question 29

Source Data Verification (SDV)

Accepted Answer

Comparing data recorded on the CRF/eCRF against the original source documents (charts, lab reports) to confirm accuracy and completeness. It is a core monitoring technique -- but under risk-based monitoring, it is no longer expected to be applied at 100%.

Question 30

Risk-Based Monitoring (RBM) under ICH E6(R3)

Accepted Answer

Shifts away from routine 100% on-site SDV toward centralized and statistical monitoring focused on the data and processes most critical to subject safety and trial reliability, guided by a documented quality risk-management/monitoring plan.

Question 31

Protocol deviation

Accepted Answer

An unplanned departure from the IRB-approved protocol or GCP that does NOT significantly affect subjects' rights, safety, or welfare, or the integrity of the study data (e.g., a visit occurring one day outside its window).

Question 32

Protocol violation

Accepted Answer

A departure from the protocol/GCP that DOES (or could) meaningfully affect subject rights, safety, or welfare, or data integrity -- it typically demands urgent corrective action/reporting and can put the study's IRB approval at risk, unlike a minor deviation.

Question 33

IRB continuing review

Accepted Answer

IRBs must re-review ongoing research at intervals appropriate to the degree of risk -- at least once every 12 months for most greater-than-minimal-risk studies -- to confirm subject protections are still adequate as the study progresses.

Question 34

Essential documents / Trial Master File (TMF)

Accepted Answer

The collection of documents that individually and collectively permit evaluation of trial conduct and data quality -- protocol, signed consent forms, IRB approvals, investigator CVs/licenses, and monitoring logs -- maintained and kept current throughout the trial.

Question 35

Investigational Product (IP) accountability

Accepted Answer

The site must maintain complete records of an investigational drug/device's receipt, storage, dispensing/use, and return or destruction, so the sponsor and FDA can confirm product was administered only to enrolled subjects per the protocol.

Question 36

Temperature excursions and IP storage logs

Accepted Answer

Storage conditions (e.g., refrigeration logs) are part of IP accountability. Any excursion outside protocol-specified ranges must be documented and reported to the sponsor/monitor for an impact assessment on product integrity and subject safety.

Question 37

Maintaining the study blind

Accepted Answer

Randomization/blinding integrity is protected through sealed codes or IWRS/IVRS systems. Unblinding is permitted only through protocol-defined emergency procedures and must be documented and reported, since improper unblinding can compromise trial validity.

Question 38

Core investigator responsibilities (21 CFR 312.60 / 812.100)

Accepted Answer

Personally conduct or supervise the investigation, ensure informed consent is obtained, comply with the protocol and applicable regulations, protect the rights/safety/welfare of subjects, and maintain adequate control over the investigational product.

Question 39

Core sponsor responsibilities

Accepted Answer

Select qualified investigators, ensure proper monitoring of the study, maintain IND/IDE compliance, ensure investigational product accountability, and evaluate and report safety information to FDA and to all participating investigators.

Question 40

Delegation of Authority (DoA) log

Accepted Answer

Documents which study-related tasks are delegated to which qualified, trained site staff members. Must be signed/dated by the delegating investigator and kept current throughout the trial to demonstrate appropriate oversight.

Question 41

ICH E6(R3) -- what is it and why does it matter for the 2026 CCRP exam?

Accepted Answer

The revised ICH Good Clinical Practice guideline, adopted in January 2025; SOCRA's exam content reflects it starting January 1, 2026. It shifts GCP's emphasis toward quality by design and proportionate, risk-based oversight rather than uniform maximal checking.

Question 42

Quality by design (ICH E6(R3))

Accepted Answer

Building quality into the protocol and trial processes from the start -- e.g., simplifying procedures and focusing on the factors critical to reliability -- rather than relying solely on inspection or monitoring to catch problems after the fact.

Question 43

Proportionality (risk-based approach) under E6(R3)

Accepted Answer

The intensity of oversight, monitoring, and documentation should scale to the risk and importance of the underlying data or process -- not be applied uniformly at maximum intensity regardless of actual risk.

Question 44

Critical data and critical processes (E6(R3))

Accepted Answer

Sponsors are directed to prospectively identify the data and processes that are critical to subject safety and the reliability of trial results, then prioritize quality-management and monitoring effort on those items.

Question 45

Fit-for-purpose technology (E6(R3))

Accepted Answer

E6(R3) supports flexible use of qualified electronic systems -- eConsent, ePRO, remote/centralized monitoring -- provided the technology is validated and appropriate for the trial's specific needs and risks.

Question 46

The close-out visit

Accepted Answer

The final monitoring visit at a site, confirming all data queries are resolved, investigational product is reconciled and returned/destroyed, essential documents are complete, and the site has fulfilled all remaining regulatory and contractual obligations.

Question 47

Record retention after study closure

Accepted Answer

Investigators/sponsors must retain essential records for at least 2 years after a marketing application for the drug/device is approved -- or, if no application is filed, for 2 years after the investigation is discontinued and FDA is notified -- whichever applies; sponsor/IRB requirements are often longer.

Question 48

Essential document archiving at closure

Accepted Answer

Completed trial documents (protocol, consent forms, CRFs, monitoring reports, correspondence) must be archived per the sponsor's/institution's retention schedule and remain readily retrievable in case of an audit or FDA inspection.

Question 49

Final regulatory notifications at study closure

Accepted Answer

The sponsor must notify FDA of the end of the investigation, and the investigator must submit a final report to the IRB documenting study closure and outcome per the institution's requirements.

Question 50

Investigational product (IP) disposition at closure

Accepted Answer

At study end, all investigational product must be fully accounted for -- returned to the sponsor, destroyed on-site with a documented certificate of destruction, or otherwise reconciled -- so accountability records reflect its final disposition.

Free CCRP Exam Flashcards

Filter by Topic

Jump to Card

About These CCRP Flashcards

Topics Covered

Frequently Asked Questions

SOCRA CCRP Certified Clinical Research Professional